StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto

About this trial

This is a prospective, single-center, phase II trial that will be monitoring the safety and efficacy of using stereotactic ablative radiotherapy (SBRT) to treat patients with a medical condition affecting heart rate and rhythm (refractory arrhythmias) within the University Health Network (Princess Margaret Cancer Centre and Toronto General Hospital). The primary objective will be to prospectively monitor patient cardiac outcomes following SBRT.

Eligibility criteria

Qualifiers

Patients with heart rate and rhythm condition (arrhythmia) who have failed standard of care treatment with medication OR at least one prior invasive catheter ablation procedure.

Patients deemed medically fit to receive stereotactic ablative radiotherapy as determined by their Radiation Oncologist.

Disqualifiers

Patients who have previously received high dose radiotherapy to the target area and cannot safely receive further treatment OR are unable to receive radiotherapy due to other contraindications.

Trial design

Treatments tested in this trial

  • Stereotactic Ablative Radiotherapy

Treatment groups

60 Participants
are divided into 2 treatment groups